Biocon stock looks good due to its strong focus on biosimilars and on contract research. The company is less vulnerable to FDA related issues and to that extent its business model is more diversified compared to other pharma stories. You can look to buy Biocon from a long term perspective, although the IPO of a subsidiary is unlikely to substantially impact the valuations of the company.